Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

Management Team

Thomas McLain, MBA, CPA

General Manager

Tom McLain has over 20 years of experience and a proven track record evolving diagnostics and biopharmaceutical companies from early-stage ventures to successful commercial organizations. Most recently as Chief Executive Officer (CEO) of Vermillion, a medical diagnostics company focused on women’s health, Mr. McLain led a strategic transformation that resulted in a fivefold increase in the company’s market capitalization. Prior to joining Vermillion, Mr. McLain was the CEO of Claro Scientific, a diagnostics start-up with a novel optics-based platform technology. He also previously served as chairman, CEO and president of Nabi Biopharmaceuticals where he led the evolution of a plasma supply-based business into a fully integrated biopharmaceutical company. Over his career, Mr. McLain has raised over $1 billion in new capital and structured numerous successful commercial alliances, joint ventures and research collaborations. Mr. McLain also served as a director, chairman of the health, safety, environment and security committee and member of the audit and finance committees at Eastman Chemical Company and as chairman of the board of Nabi Biopharmaceuticals. He has been active in the life sciences industry, serving as Chairman of the Board of BioFlorida for seven years and as a board member of the Biotechnology Industry Organization and the Southeastern Medical Device Association. Mr. McLain earned his BA at the College of the Holy Cross, and his MBA from the University of Rochester.


Johan Skog, PhD

Chief Scientific Officer and Founding Scientist

Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other microvesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Dr. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Dr. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden.


William J. Kelly, CPA

Chief Financial Officer

William Kelly has over 20 years of financial management experience, including senior roles at emerging, international, publicly traded life science companies. Prior to joining Exosome Diagnostics, Mr. Kelly served in executive positions such as Chief Financial Officer (CFO) of RepliGen Corporation and Corporate Controller of Haemonetics. While at RepliGen Corporation, Mr. Kelly helped lead the company through a transformation from a research entity valued at $100M to a commercial enterprise worth over $600M. He began his financial career as an auditor at leading financial firms Deloitte & Touche and Ernst and Young. Mr. Kelly is a Certified Public Accountant who holds a BA in psychology from the College of the Holy Cross and an MS/MBA from Northeastern University.


Mikkel Noerholm, PhD

Vice President Product Development

Mikkel Noerholm heads European operations for Exosome Diagnostics from the company’s site in Munich, Germany. He previously served as Research Scholar at Massachusetts General Hospital/Harvard Medical School where he worked closely with Dr. Skog to develop exosome technology. Dr. Noerholm’s previous corporate experience includes being instrumental in establishing Exiqon, Inc., where he held the role of Director of Technical Support. He also previously served as R&D Project Manager at Exiqon A/S in Denmark, where he led the development of what is now that company’s miRCURY LNA Arrays. Dr. Noerholm has a PhD in micro- and biotechnology from the Technical University of Denmark and an MBA from Babson College.